£28.31
+
£0.69 (2.44%)
End-of-day quote: 05/18/2024
CASE:BIOC
GlaxoSmithKline S.A.E Competitors
| Ticker | Name | Exchange | Consensus | Price | Price Target | Upside/Downside | Analysts | Market Cap |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and | NYSE | Outperform | $770.00 | $636.99 | 0.00% | 9 | $693.31B |
| NOVO B | Novo Nordisk A/S | CPSE | Outperform | kr903.30 | kr696.07 | 0.00% | 14 | kr4.01T |
| ABBV | AbbVie | NYSE | Outperform | $166.42 | $178.42 | 0.00% | 11 | $293.88B |
| AZN | AstraZeneca PLC | LSE | Outperform | £121.10 | £165.99 | 0.00% | 16 | £187.73B |
| ROG | Roche Holding | SWX | Hold | CHF237.10 | CHF307.83 | 0.00% | 9 | CHF191.28B |
| PFIZER | Pfizer | NSEI | Outperform | Rp4.47k | Rp4.53k | 0.00% | 3 | Rp204.63B |
